Читать книгу Blood and Marrow Transplantation Long Term Management - Группа авторов - Страница 109

New‐onset thyroid disease is one of the most common non‐malignant late effects after AHSCT, with a cumulative incidence of 14.2% [3]. The median time to diagnosis from transplant is approximately 1 year [3]. A Spanish study on 169 AHSCT survivors has identified thyroid dysfunction in 62 (37%) patients, with subclinical hypothyroidism, overt primary hypothyroidism, and subclinical hyperthyroidism in 54, 6, and 2 patients respectively [35]. Transient subclinical hypothyroidism can be seen in 16% of patients at 3 months posttransplant, which typically disappears at 12 months [36]. A Swedish study on 111 AHSCT survivors showed thyroid dysfunction in 20 patients, 16 of whom had received prior TBI. Notably, in patients who developed thyroid dysfunction, pretransplant thyroid stimulating hormone (TSH) level was significantly higher compared to those who did not. All patients should have at least yearly thyroid function screening after transplant 17,18]. Patients should also be educated regarding signs and symptoms of hypo‐ and hyperthyroidism.